Process Development Technologist

Process Development Technologist in exciting Norwegian biotech company.

 

Oncoinvent AS is looking for a Process Development Technologist in the Production department at the company manufacturing facility in Oslo. The position is an exciting opportunity to work in an innovative and dynamic start-up company and participate in the development of novel pharmaceuticals.

The Process Development Technologist is responsible for translating laboratory-scale processes into robust, efficient, and commercially viable production processes. The role involves upscaling, optimization, and continuous improvement of production methods to ensure high-quality, cost-effective, and compliant manufacturing. Working closely with the other functional units and Contract Manufacturing Organisation (CMO’s), the technologist bridges the gap between development and full-scale commercial operation.

The successful candidate will collaborate with cross-functional teams and be responsible for ensuring that the production methods of the raw materials, intermediates and drug product (Radspherin®) are developed into commercially viable processes.

This position may require hands-on work with radioactive materials. A successful candidate will therefore receive extensive training and is expected to comply with radiation protection and other health and safety procedures during laboratory- and production scale experiments, and GMP production activities.

Key responsibilities

  • Process Upscaling: Transfer laboratory-scale and pilot-scale processes to commercial manufacturing scale.
  • Process Optimization & Improvement: Optimize process parameters while maintaining product quality through data-driven approaches. Look for continuous improvement opportunities.
  • Technology Transfer & Implementation: Collaborate with cross-functional teams to transfer processes into GMP production. Support validation, qualification, and troubleshooting activities.
  • Commercial Readiness: Ensure processes comply with regulatory and quality standards (e.g., GMP, ICH guidelines) and with process control strategies suitable for long-term commercial operation. Participate in risk assessments and process failure mode analyses (pFMEAs).

Qualifications and experience

The holder of the Production Scientist position should have the following documented qualifications and experience:

  • Degree in Biotechnology, Chemical Engineering, or related fields (M.Sc. or Ph.D.).
  • Experience in process development, scale-up, or manufacturing support.
  • Strong understanding of manufacturing processes, in particular suspensions, microparticles and preferably radiochemistry.
  • Familiarity with GMP, regulatory requirements, and process validation principles.
  • Proficiency in data analysis, process modelling, and experimental design.
  • Strong problem-solving, communication, and cross-functional collaboration skills.
  • Norwegian and English language skills.

Location

The holder of this position will be based at Oncoinvent AS, Gullhaugveien 7, 0484 Oslo. The position will report to the Chief Production Officer.

 

Application deadline: We are reviewing candidates on a rolling basis.

Please submit your application with a motivational letter stating “why Oncoinvent” and what you can contribute to the position as well as an updated CV. Application without this will not be reviewed further.

Om arbeidsgiveren

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin in a clinical development program in two indications. In addition to the finalized phase 1/2a trial in colorectal cancer, one Phase 1 trial and one randomized Phase 2 trial, both in ovarian cancer are ongoing in the US, UK and Europe. Preliminary clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo (ONCIN:OL).

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.